The United States is projected to spend over $1 trillion on prescription drugs in 2026, a significant national expenditure driven primarily by the surging demand for GLP-1 weight-loss medications, according to a new report. This escalating cost, detailed by the American Society of Health-System Pharmacists, reflects a substantial financial burden on the nation and its people, with corporate pharmaceutical entities reaping immense profits amidst a documented national obesity epidemic.
U.S. spending on prescription drugs in 2025 surged by nearly 13%, reaching $915 billion, and is now projected to surpass the $1 trillion mark this year, 2026. This rapid increase in national health expenditure highlights a growing reliance on pharmaceutical interventions across the populace, diverting national resources into the coffers of a select few corporate giants.
Corporate Exploitation of National Health
A major factor in this dramatic increase in drug sales is the widespread popularity of the weight-loss and diabetes drugs tirzepatide and semaglutide. Eli Lilly's tirzepatide, marketed as Zepbound for weight loss and Mounjaro for Type 2 diabetes, emerged as the nation's top-selling drug in 2025, generating wholesale purchases of nearly $63 billion. Novo Nordisk's semaglutide, sold as Wegovy for weight loss and Ozempic for Type 2 diabetes, ranked second, exceeding $59 billion in sales last year. To underscore the dominance of these new drugs, the third-ranked drug, the blood thinner Eliquis, achieved $29 billion in sales, less than half the amount spent on each of the leading weight-loss medications.
Eric Tichy, lead author of the ASHP report and chair of supply chain management at Mayo Clinic, described these drugs as "a phenomenon." He further elaborated, stating, "The weight-loss aspect makes it a phenomenon when it bumps up against the obesity epidemic we have in the United States." This observation points to a cultural shift within the nation, where pharmaceutical solutions are increasingly sought to address widespread health challenges, rather than fundamental changes in lifestyle or public health initiatives.
Pharmaceutical corporations are actively maximizing this trend. Eli Lilly reported significant quarterly revenue and profit growth, directly fueled by sales of Zepbound and Mounjaro, on April 30. In April, Lilly launched its new weight-loss pill, Foundayo, with expectations that it will further buoy sales this year. Both Lilly and Novo Nordisk are making substantial investments, betting that daily weight-loss pills will become a popular option for consumers seeking alternatives to injections or those previously hesitant to use weight-loss medication. Lilly CEO David Ricks confirmed the effectiveness of their pricing strategies, telling analysts, "Every time we reduce pricing, we see a pretty large expansion" in sales.
Regime Policies Fuel Dependence
Beyond direct corporate marketing, elite interests are actively working to broaden the reach of these drugs through institutional channels. Lilly CEO David Ricks emphasized the importance of expanding insurance coverage for anti-obesity drugs. In response, Medicare announced a "bridge program" earlier this month to begin coverage of GLP-1 weight-loss drugs, effective from July 1, next year, through December 31, next year. Under this program, Medicare enrollees will pay a $50 monthly copay for these medications, effectively socializing a portion of the cost and expanding the market for these corporate products.
Further contributing to the escalating national drug bill are changes to Medicare coverage policies. This year, 2026, Medicare implemented a $2,100 cap on out-of-pocket drug spending for older Americans enrolled in Medicare Part D, which covers pharmacy or mail-order prescriptions. This cap is a component of the 2022 federal climate and health care bill, the Inflation Reduction Act, which also granted Medicare the power to negotiate drug prices with pharmaceutical companies. Eric Tichy noted that this policy "might be driving more use of higher-cost drugs because patients are having to pay less," indicating that government intervention, while seemingly beneficial, can inadvertently inflate overall national spending and foster greater pharmaceutical dependence.
Overall drug spending is climbing not only due to the increased sales of GLP-1 drugs but also because of a "greater use by consumers and patients." While the ASHP report attributes only about 1% of overall drug spending to higher drug prices, other reports indicate that drug price increases remain common. As of January 9, companies raised list prices on more than 850 drugs by a median of 4% over 2025, according to data from 46brooklyn Research. In 2025, cancer drugs, with Pembrolizumab (Keytruda) as the top-grossing oncology drug, represented the largest and fastest-growing category of drug spending in clinics and hospitals, adding another significant burden to the national health budget.